1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,371 | 0,388 | 11:59 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:02 | Cantargia Publishes Annual Report 2025 | 111 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 17, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that the annual report for 2025 has been published. The Annual Report is attached to this press... ► Artikel lesen | |
| 08:02 | Notice of Annual General Meeting in Cantargia AB | 111 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 17, 2026 / Cantargia (STO:CANTA) - The shareholders of Cantargia AB (publ), reg. no. 556791-6019, are invited to the annual general meeting on Thursday, 21 May 2026... ► Artikel lesen | |
| CANTARGIA Aktie jetzt für 0€ handeln | |||||
| 05.03. | Cantargia to Participate at Van Lanschot Kempen's Life Sciences Conference | 404 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 5, 2026 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that members of Cantargias management will participate in one-on-one meetings... ► Artikel lesen | |
| 23.02. | Cantargia to Participate in TD Cowen's Annual Healthcare Conference | 390 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 23, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that members of Cantargia's management will participate in and host 1-1 meetings... ► Artikel lesen | |
| 20.02. | Cantargia Publishes Full Year Report 2025 | 275 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 20, 2026 / Cantargia AB's (publ) ("Cantargia") (Nasdaq Stockholm:CANTA)(STO:CANTA) full year report for 2025 is now available on the company's web page www.cantargia.com/en/investors/financial-reports."Cantargia... ► Artikel lesen | |
| 06.02. | Invitation to the Presentation of Cantargia's Annual Results for 2025 | 309 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 6, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's annual results report for 2025 on Friday, February 20, 2026, at 07:00 a.m. CET.In... ► Artikel lesen | |
| 28.01. | Cantargia to Participate at Leerink Partners Global Healthcare Conference | 285 | ACCESS Newswire | LUND, SE / ACCESS Newswire / January 28, 2026 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that members of Cantargias management will participate in one-on-one... ► Artikel lesen | |
| 23.01. | Cantargia Reports First Patient Dosed in New US Investigator-Initiated Colorectal Cancer Study | 226 | ACCESS Newswire | LUND, SE / ACCESS Newswire / January 23, 2026 / Cantargia AB (Publ) (STO:CANTA) today reported that the first patient has been dosed in a Phase 1b/2 clinical trial investigating nadunolimab in combination... ► Artikel lesen | |
| 05.12.25 | Cantargia Provides Update on Overall Survival Data from TRIFOUR | 285 | ACCESS Newswire | LUND, SE / ACCESS Newswire / December 5, 2025 / Cantargia (STO:CANTA) - Cantargia AB (Publ) (NASDAQ:CANTA.ST) today announced an update on overall survival results from the Phase 1b/2 TRIFOUR study... ► Artikel lesen | |
| 19.11.25 | Cantargia Q3 2025: Erster Gewinn durch transformativen Otsuka-Deal | 7 | Investing.com Deutsch | ||
| 19.11.25 | Cantargia Q3 2025 slides: First-ever profit driven by transformational Otsuka deal | 7 | Investing.com | ||
| 19.11.25 | Earnings Call Transkript: Cantargia meldet im 3. Quartal 2025 erstmals Umsatzerlöse | 4 | Investing.com Deutsch | ||
| 19.11.25 | Cantargia Publishes Interim Report for January to September 2025 | 355 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 19, 2025 / Cantargia AB (publ) ("Cantargia") (STO:CANTA) issued its interim report for the period January until September 2025. The report is now available on the... ► Artikel lesen | |
| 12.11.25 | Cantargia Presents Nomination Committee Ahead of 2026 AGM | 322 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 12, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today provided notification that the Nomination Committee (NC) has been appointed... ► Artikel lesen | |
| 05.11.25 | Invitation to the Presentation of Cantargia's Interim Report January-September 2025 | 278 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 5, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's interim report for the first nine months of 2025 on Wednesday... ► Artikel lesen | |
| 23.10.25 | Cantargia to Participate in Upcoming Conferences | 326 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 23, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that management will participate in the following investor conferences.Stifel... ► Artikel lesen | |
| 02.10.25 | Cantargia Appoints Dr. Wolfram Dempke As Chief Medical Officer | 364 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 2, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm: CANTA) today announced the appointment of Wolfram Dempke, MD, PhD, MBA as Chief Medical... ► Artikel lesen | |
| 01.10.25 | Cantargia Presents Data at an AACR Conference Strengthening IL1RAP as a Targetable Hallmark in PDAC | 456 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 30, 2025 / Cantargia (STO:CANTA)High IL1RAP protein expression on tumor cells is linked to poor survival in PDAC patients treated with chemotherapy, while this... ► Artikel lesen | |
| 11.09.25 | Cantargia Closes the Acquisition of CAN10 by Otsuka | 443 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 11, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that Cantargia and its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) have closed Otsuka's... ► Artikel lesen | |
| 27.08.25 | Cantargia Granted Important US Patent for Nadunolimab | 354 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 27, 2025 / Cantargia AB (Publ), Nasdaq Stockholm:CANTA, (Cantargia) today announced that the United States Patent and Trademark Office (USPTO) has granted the patent... ► Artikel lesen |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 87,75 | +1,27 % | BERENBERG stuft Biontech auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Biontech mit einem Kursziel von 155 US-Dollar auf "Buy" belassen. Die Produktpipeline des Antikörperspezialisten stehe wieder... ► Artikel lesen | |
| EVOTEC | 5,570 | 0,00 % | DEUTSCHE BANK RESEARCH stuft Evotec auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Evotec mit einem Kursziel von 4,5 Euro auf "Hold" belassen. Die Eckdaten hätten sich bestätigt, schrieb Fynn Scherzler in... ► Artikel lesen | |
| QIAGEN | 35,190 | +0,54 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 625,50 | -1,20 % | Regeneron und Sanofi bekommen Dupixent-Zulassung für Kinder mit CSU | DJ Regeneron und Sanofi bekommen Dupixent-Zulassung für Kinder mit CSU
Von Colin Kellaher
DOW JONES--Regeneron Pharmaceuticals und Sanofi haben für ihren Blockbuster-Entzündungshemmer Dupixent... ► Artikel lesen | |
| BRAIN BIOTECH | 2,470 | +2,92 % | EQS-News: BRAIN Biotech AG: BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Patent
BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie
23.03.2026 / 11:05 CET/CEST
Für... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| CARDIOL THERAPEUTICS | 1,154 | -2,53 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart | Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the... ► Artikel lesen | |
| CSL | 83,85 | +0,61 % | Down 38% this year, is it finally time to buy low on CSL, ResMed and Pro Medicus shares? | ||
| BURCON NUTRASCIENCE | 1,350 | -1,46 % | Burcon NutraScience Corporation: Burcon Closes Second Tranche of Non-Brokered Private Placement of Convertible Debentures of up to $6.9 Million | Vancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| MANNKIND | 2,365 | +1,50 % | Leerink reiterates Outperform on MannKind stock, sees overreaction | ||
| OCULAR THERAPEUTIX | 7,450 | -1,32 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD | New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI's unmatched durability in wet AMD with sustained disease control AXPAXLI demonstrated robust CSFT control with a median time of 39 weeks... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,385 | +0,22 % | Oxford Nanopore Tech - Director/PDMR Shareholding - LTIP and DBP awards | ||
| ADAPTIMMUNE THERAPEUTICS | 0,013 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| CODEXIS | 1,989 | -7,92 % | CODEXIS, INC. - 8-K, Current Report | ||
| CORMEDIX | 5,984 | -1,19 % | CorMedix, Inc.: CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | - Q4 2025 Net Revenue of $128.6 million - Pro Forma Full Year 2025 Net Revenue of $401.3 million - Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million - Conference Call Scheduled... ► Artikel lesen |
Das Unternehmen CANTARGIA AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,11 % bei einem Aktienkurs von 0,355 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANTARGIA AB finden Sie auf Wallstreet Online.